Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR031 in GPC3+ Squamous Cell Lung Cancer
NCT07444281Phase 1Recruiting
- Sponsor
- AbelZeta
- Start
- Dec 2024
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD5851 in squamous cell carcinoma of the lung (LSCC) (2 arms), sponsored by AbelZeta. Primary endpoints: Adverse Events at 28 days and Dose-Limiting Toxicity at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
AZD5851
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT07444281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444281.